Dinucleoside polyphosphates: Newly detected uraemic compounds with an impact on leucocyte oxidative burst

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2636-2644

  Schepers, Eva ^a   Glorieux, Griet ^a   Jankowski, Vera ^b   Dhondt, Annemieke ^a   Jankowski, Joachim ^b   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cardiovascular disease; cell activation; chronic kidney disease; oxidative stress; uraemic toxins

Indexed keywords

ADENOSINE GUANOSINE TETRAPHOSPHATE; DIADENOSINE HEXAPHOSPHATE; DIADENOSINE TETRAPHOSPHATE; DIADENOSINE TRIPHOSPHATE; DIGUANOSINE TETRAPHOSPHATE; DINUCLEOSIDE PHOSPHATE; DINUCLEOSIDE POLYPHOSPHATE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GUANOSINE DERIVATIVE; NUCLEOSIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATE; RADICAL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UREMIC TOXIN; URIDINE ADENOSINE TETRAPHOSPHATE; URIDINE DERIVATIVE;

ARTICLE; BLOOD; BLOOD SAMPLING; CELL STIMULATION; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRANULOCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE ACTIVATION; LYMPHOCYTE; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY BURST; UREMIA; VASOCONSTRICTION; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECTS; KIDNEY DISEASE; METABOLISM;

CHRONIC DISEASE; DINUCLEOSIDE PHOSPHATES; HUMANS; KIDNEY DISEASES; LEUKOCYTES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; TETRADECANOYLPHORBOL ACETATE; UREMIA;

EID: 77954770320     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq080     Document Type: Article

References (45)

1. Van Biesen W, De Bacquer D, Verbeke F et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28: 478-483
2. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
3. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial 2004; 17: 449-454
4. Massy ZA, Maziere C, Kamel S et al. Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 2005; 20: 380-382
5. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif2001; 19: 143-151
6. Stenvinkel P, Carrero JJ, Axelsson J et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521
7. Vanholder R, Glorieux G, Lameire N. Uraemic toxins and cardiovascular disease. Nephrol Dial Transplant 2003; 18: 463-466
8. Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease? Curr Opin Nephrol Hypertens 2007; 16: 506-511
9. Vanholder R, Meert N, Schepers E et al. Uremic toxins: do we know enough to explain uremia? Blood Purif 2008; 26: 77-81
10. Ward RA, Greene T, Hartmann B etal. Resistance to intercompartmen- tal mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006; 69: 1431-1437
11. Vanholder R, Schepers E, Meert N et al. What is uremia? Retention versus oxidation. Blood Purif 2006; 24: 33-38
12. Vanholder R, Van Laecke S, Glorieux G. The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol 2008; 21: 146-160
13. Jankowski J, Jankowski V Laufer U et al. Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol 2003; 23: 1231-1238
14. Luo J, Jankowski V, Gungar N et al. Endogenous diadenosine tetrapho- sphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue. Hypertension 2004; 43: 1055-1059
15. Ogilvie A, Blasius R, Schulze-Lohoff E et al. Adenine dinucleotides: a novel class of signalling molecules. J Auton Pharmacol 1996; 16: 325-328
16. Schluter H, Grobeta I, Bachmann J et al. Adenosine(5') oligopho- spho-(5') guanosines and guanosine(5') oligophospho-(5') guano- sines in human platelets. J Clin Invest 1998; 101: 682-688
17. Jankowski J, Hagemann J, Yoon MS et al. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001; 59: 1134-1141
18. Jankowski V, Tolle M, Vanholder R et al. Uridine adenosine tetrapho- sphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005; 11: 223-227
19. Baxi MD, Vishwanatha JK. Diadenosine polyphosphates: their biological and pharmacological significance. J Pharmacol Toxicol Methods 1995; 33: 121-128
20. Hoyle CHV, Hilderman RH, Pintor JJ et al. Diadenosine polypho- sphates as extracellular signal molecules. Drug Dev Res 2001; 52: 260-273
21. Flores NA, Stavrou BM, Sheridan DJ. The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc Res 1999; 42: 15-26
22. Jankowski V, Meyer AA, Schlattmann P et al. Increased uridine ad- enosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol 2007; 27: 1776-1781
23. Jankowski V, Karadogan S, Vanholder R et al. Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polypho- sphates released from proximal tubule epithelial cells. Kidney Int 2007; 71: 994-1000
24. Ralevic V, Jankowski J, Schluter H. Structure-activity relationships of diadenosine polyphosphates (Ap(n)As), adenosine polyphospho gua- nosines (Ap(n)Gs) and guanosine polyphospho guanosines (Gp(n)Gs) at P2 receptors in the rat mesenteric arterial bed. Br J Pharmacol 2001; 134: 1073-1083
25. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3: 1541-1554
26. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126
27. Zalba G, Fortuno A, Diez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2686-2690
28. Ng KE, Orgel LE. The action of a water-soluble carbodiimide on ad- enosine-5'-polyphosphates. Nucleic Acids Res 1987; 15: 3573-3580
29. Jankowski J, Potthoff W, Zidek W et al. Purification of chemically synthesised dinucleoside(5',5')polyphosphates by displacement chro- matography. J Chromatogr B Biomed Sci Appl 1998; 719: 63-70
30. Cohen G, Glorieux G, Thornalley P et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390
31. Ogilvie A. Extracellular functions for ApnA. In: AG McLennan (ed). Ap4A and Other Dinucleoside Polyphosphates. Boca Raton: CRC Press, 1992; 230-273
32. Schepers E, Meert N, Glorieux G et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596
33. Grundler W, Dirscherl P, Beck-Speier I et al. Simultaneous recording of calcium transients and reactive oxygen intermediates of human polymorphonuclear granulocytes in response to formyl-Met-Leu-Phe and the environmental agent sulfite. Cytometry 2000; 40: 219-229
34. Ward RA, McLeish KR. Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003; 27: 230-236
35. Ralevic V Hoyle CH, Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinu- cleotides in rat mesenteric arteries. J Physiol 1995; 483: 703-713
36. Ralevic V Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-492
37. Bernhard MK, Ulrich K. Rt-PCR study of purinergic P2 receptors in hematopoietic cell lines. Biochemistry (Mosc) 2006; 71: 607-611
38. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 1998; 336: 513-523
39. Gasmi L, McLennan AG, Edwards SW. Priming of the respiratory burst of human neutrophils by the diadenosine polyphosphates, AP4A and AP3A: role of intracellular calcium. Biochem Biophys Res Commun 1994; 202: 218-224
40. Gasmi L, McLennan AG, Edwards SW. The diadenosine polypho- sphates Ap3A and Ap4A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutro- phil apoptosis: implications for neutrophil: platelet interactions during inflammation. Blood 1996; 87: 3442-3449
41. Gasmi L, McLennan AG, Edwards SW. Neutrophil apoptosis is delayed by the diadenosine polyphosphates, Ap5A and Ap6A: syner- gism with granulocyte- macrophage colony-stimulating factor. Br J Haematol 1996; 95: 637-639
42. Gasmi L, McLennan AG, Edwards SW. Diadenosine polyphosphates induce intracellular Ca2+ mobilization in human neutrophils via a pertussis toxin sensitive G-protein. Immunology 1997; 90: 154-159
43. Vartanian A, Narovlyansky A, Amchenkova A et al. Interferons induce accumulation of diadenosine triphosphate (Ap3A) in human cultured cells. FEBS Lett 1996; 381: 32-34
44. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
45. Jankowski V, Patzak A, Herget-Rosenthal S et al. Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. JMol Med 2008; 86: 333-340